What will be the next blockbuster research to emerge from Princeton’s labs? No one can say for sure, but history tells us ...
The FDA has cleared the initiation of a pivotal Phase 3 trial testing pridopidine in people with early, rapidly progressive ...
PathMaker Neurosystems Inc. ('PathMaker”), a clinical-stage neurotechnology company developing a breakthrough non-invasive approach for treating Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s ...
Faced with a bleak prognosis of ALS, 35-year-old Megan Decker, along with her husband, Joey, "want to make as many memories as possible with our children while mommy is still here." ...
Qalsody is one step closer to being covered by public Canadian healthcare systems when used to treat adults with ALS with ...
The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and ...
Today, after receiving a gene therapy developed at the University of California San Diego, Natalie is thriving at 34 years ...
A Northwestern Medicine study has shed light on a critical molecular mechanism underlying amyotrophic lateral sclerosis (ALS) ...
The man behind the Moose Jaw health centre that has claimed “a 100 per cent success rate in stopping the progression and in ...
Highlights:FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official entry ...
AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS PRIOR ANY COMPLETE LOSS OF FUNCTION Significant improvement in ...
Researchers developed a blood test that spots ALS with 90% accuracy. The 46-gene panel could cut diagnostic delays that now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback